AstraZeneca (AZ)


AstraZeneca is proud to be a part of the WIPO Re:Search initiative, which we joined as a founding member in 2011, and we are committed to sharing our intellectual property with prospective partners who have the same passion for advancing research in neglected tropical diseases, including TB and malaria. AstraZeneca is proud to make a commitment that all patents owned by AstraZeneca or MedImmune should be used to promote  NTD R&D and will therefore be available for royalty-free licensing under the terms of the WIPO Re:Search Guiding Principles. In view of this commitment, AZ is contributing the entire portfolio of patents and published patent applications which it owns, to WIPO Re:Search for license as above, subject only to any conflicting obligations to third parties existing prior to the request for such license. There is no intention to imply that all our contributed patent rights will have relevance to NTDs but in making this broad commitment we make clear that any such rights will be available to promote NTD R&D anywhere in the world [ID 1421]. Since we are taking a whole portfolio approach to our patent contribution, we will not list all patent rights contributed, because AstraZeneca patents can easily be identified on public databases such as WIPO’s. Some patents which we believe will be of immediate relevance for NTDs have been included in Re:Search at launch and are mentioned below. We will work with Users to specifically identify patents of particular interest and amend the website to make specific reference to these.
In addition to this general patent contribution, we are making the following technical contributions to improve significantly the chances of shorter-term real world R&D benefits:
  • Two Lead series DNA Gyrase inhibitors with utility in TB [881, 901]
  • Access to 28 mature, selective chemical assets candidates and information (e.g., physical / chemical properties; biochemical activity; synthetic route) from abandoned AZ Infection and non-Infection drug projects against 19 diverse biological mechanisms, suitable for use as probes in NTDs [1102 1122 1123 1124 1161 1404 1461]
  • AZD5847 for TB; Compound for pre-clinical studies. [1141]
  • Enabling Technology patents covering screening assay methods applicable to TB research
  • AZ will commit to enabling up to 3 full collection or large library screens per annum using the AZ compound collection, to identify and determine potency of small molecule hits against novel targets for NTDs [1403]. The screens will be performed within AZ’s corporate High Throughput Screening facilities.
    •  It is expected that the screens would be developed and performed by individuals from external academic groups, who will receive appropriate training in screening and data analysis from AZ scientists, and enabling support in terms of compound plating.
    • These screens will be performed within AZ’s corporate High Throughput Screening facilities. The visiting scientists would be expected to ensure they have external funding covering salary, accommodation, and consumables expenses for this work; further HI and LI workup on selected active molecules would be expected to be performed by them in their home facilities.
  • AZ will also consider approaches by external NTD scientists wishing to work on their targets in AZ labs (e.g., in Infection IMed at Bangalore or Boston; and/or in DECS at Boston or Alderley Park). Guest scientists would benefit from scientific mentoring and access to state-of-the-art equipment at AZ, and would be expected to have secured funding to support their travel and living expenses. [1443]
  • AZ will consider requests to assist external NTD research workers scientifically with computational and predictive chemistry. [1442]
Improving health is one of the toughest challenges facing the world today. As a global biopharmaceutical company, AstraZeneca has a key contribution to make through the discovery, development, manufacturing, and commercialization of innovative medicines for some of the world’s most serious diseases, including infection. We know that if we are to deliver medicines that people really need and value, we can’t do it in isolation. So we work closely with our stakeholders to understand their challenges and how we can combine forces to drive continued progress in healthcare. Our goal is always to improve health for patients and bring benefit for our stakeholders, our business, and society.